Akero Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy AKRO

*Your capital is at risk

$54.65

+0 (+0%)

At Close: Mar 06, 2026

Currently predicting for Thu, 6 Aug 2026

AKRO Live board

Community Bull/Bear

Target Next close

Join the AKRO prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

AKRO Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For AKRO

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

AKRO Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT AKERO THERAPEUTICS INC.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
FCX $62.63	7.46%	Jul 31
MC $67.08	2.40%	Jul 31
ARW $212.85	6.96%	Jul 30
BIIB $202.19	3.10%	Jul 24
F FERG $230.67	10.77%	Jul 24

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by